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The possible use of the blood serum 
concentration measurements of sHLA-G 
in women with endometrial and cervical 
cancers during radiotherapy as an 
indicator of the status of the tumour 
microenvironment
ABSTRACT
Background: The selective suppression of cytotoxic immune cells constitutes a crucial event in the devel-
opment of malignancy. This phenomenon increases in accordance with the growth of a tumor and is just 
one result of the increased expression in the cancer milieu of those proteins, such as human leukocyte 
antigen G (HLA-G) and its soluble form (sHLA-G). Given that radiotherapy may influence immune sys-
tem activity, we aimed to measure (sHLA-G) serum levels both before and after the radiotherapy due to 
endometrial or cervical cancer. 
Methods: We assessed the sHLA-G blood serum concentration levels in a group of 43 patients (28 and 
15 diagnosed with cervical cancer and endometrial cacer respectively), who received primary or adjuvant 
radiotherapy. We assessed the blood serum concentrations of the sHLA-G through a series of measure-
ments taken before and four days after the latest radiation dosage using an ELISA kit. 
Results: Median serum sHLA-G levels significantly decreased after radiotherapy (5.63 U/ml; range 0.00 
– 344.55; vs 5.57 U/ml; 0.00 –94.02; P = 0.045). The changes of sHLA-G levels didn’t influence patients’ 
survival. Pretreatment and post-treatment sHLA-G levels were negatively correlated with patients’ age (R 
Spearman = -0.45, P = 0.041; R Spearman = -0.46. P = 0.038).
Conclusions: The detected levels of sHLA-G blood serum concentrations may supply clinically applicable 
information regarding the status of the tumor microenvironment — that is, the size and  the degree of 
suppression of the tumor environment — where the tumor-immune cell interaction is realized. Finally, this 
information may also prove helpful in the treatment of cancer.
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Introduction
The suppression of the immune system constitutes 
a crucial event in the development of malignancy. It is 
known that this phenomenon increases in accordance 
with the growth of a tumour as a result of the increased 
expression in the cancer milieu of the proteins responsi-
ble for the evasion of cancer cells from immune system 
surveillance. The suppressive environment is related 
not only to the membrane form of expression, but also 
to the secretion of the soluble form of these proteins, 
such as Fas-L [1], RCAS1 [2–3], and HLA-G [4], to the 
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extracellular matrix of the cancer microenvironment. 
This profile of the microenvironment is also determined 
by the infiltration of immune regulatory cells (e.g., Treg) 
into the cancer microenvironment itself [5] and to the 
polarization of the tumour microenvironment by an 
increase in Th2 cytokine (e.g., IL-10) concentration [6]. 
Tylor et al. have demonstrated that the recruitment of 
Tregs to the cancer microenvironment inhibits an effec-
tive antitumor immune response [7]. It has been shown 
that radiotherapy affects the function of the immune 
system. Muroyama et al. have shown that RT-induced 
proliferation of Treg cells and the post-RT intratumoral 
Treg cells have a suppressive function [8]. Generally, 
the clinical studies suggest that radiotherapy increase 
the production of Tregs and their recruitment to local 
tumour microenvironment [9].
The presence of these factors in the tumour micro-
environment may be discerned in the cancer milieu. 
Furthermore, the levels of its expression or the con-
centrations of its soluble forms can be determined not 
only in the tumour microenvironment but also in the 
peripheral blood. Since these factors are crucial for 
the development of the phenomenon, the possibility 
of assessing the levels in women treated for gynaeco-
logical malignancies would seem to constitute a clin-
ically applicable indicator of the status of the tumour 
microenvironment — that is, the size and the degree 
of suppression of the tumour environment. Most likely, 
the use of the information deriving from the interactions 
between cancer and its stroma and the immune cells in 
the tumour microenvironment will spur improvement in 
the therapy for gynaecological malignancies. As of now, 
treatment for endometrial cancers remains a clinical 
problem [10]. 
We focused on our studies on the cancer microenvi-
ronment and on the proteins present there and deriving 
from the cancer milieu. Most likely such proteins like 
HLA-G can be used as biomarkers not specifically linked 
with the particular type of gynaecological malignancy, 
as they have also been found under normal physiolog-
ical conditions in women’s reproductive tracts (e.g., 
in the feto-maternal interface) [11]. The blood serum 
profiles of these biomarkers may supply interesting in-
formation for clinicians, such as the fact that developing 
cancer modifies its own microenvironment.
HLA-G is an antigen whose participation in the 
regulation of the immune system has been well doc-
umented [11]. HLA-G is one of the proteins involved 
in the regulation of the interaction of the tumour and 
immune cells that takes place in the microenvironment 
of a growing tumour [12, 13]. HLA-G is believed to 
protect the target cells that are deficient in HLA class 
I antigens from NK-dependent lysis by interacting on 
their surfaces with killer-inhibitory receptors. Tumour 
cells may, therefore, be excluded from the host immune 
response. Expression of the suppressive molecule 
HLA-G differs from that found in other types of malig-
nancies. In general, an increased expression of HLA-G 
is known to be associated with disease progression 
not only in ovarian [14], endometrial [15], and breast 
[16] cancers, but also in non-gynaecological types of 
malignancies, such as bladder cancers [17], and ret-
inoblastoma [18]. Park et al. have demonstrated that 
cells can generate the soluble HLA-G (HLA-G1 and 
HLA-G5) by the dual mechanism of alternative splicing 
and proteolytic shedding and that the soluble form 
of HLA-G is able to inhibit the lytic activity of NK cells 
[11]. The concentration of the soluble form of sHLA-G 
in the peripheral blood could demonstrate the level of 
suppression by the tumour environment. Ben Yahia et 
al. have demonstrated the growth of sHLA-G in early 
stages (Stages I and II) as well as the correlation with 
grading of endometrial cancer. The alteration of the 
level of sHLA-G was associated with the rapid spread 
of the disease [19].
The presence in the peripheral blood proteins such 
as sHLA-G might be related to the suppressive influence 
of cancer cells on the immune system. This information 
detected in peripheral blood is valuable and applicable 
especially from a clinical point of view. For this reason, 
we decided in our study to evaluate the sHLA-G blood 
serum concentration levels both before and after the 
radiotherapy in patients treated for cervical and endo-
metrial carcinomas. 
Material and methods
Human subject
In the case of early-stage cervical cancer patients 
(up to and including IB1 according to FIGO classi-
fication) a radical hysterectomy and adnexectomy 
with pelvic and paraaortic lymphadenectomy were 
performed followed by brachytherapy and external 
beam radiation. More advanced stages were treated 
with primary radiotherapy with or without concurrent 
chemotherapy. Patients with endometrial cancer were 
treated surgically in all cases and simple, extrafascial 
hysterectomy with bilateral ovariectomy with pelvic 
lymphadenectomy was performed. All of the analyzed 
patients with endometrial cancer were treated with ad-
juvant external beam radiation and brachytherapy with 
or without chemotherapy. The mean age of the patients 
included was 58 (range 35–84 years). The patients had 
undergone treatment in the Gynecologic Oncology De-
partment of the M. Sklodowska-Curie Memorial Institute 
or in the Gynecology and Oncology Department of the 
Lukaszczyk Oncological Center, respectively in Krakow 
and Bydgoszcz between January 2007 and September 
2010. The patient’s consent was obtained in each case. 
Prior to the study, the approval of the Jagiellonian Uni-
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versity Ethical Committee (KBET/135/B/2007) was 
also obtained. Information on all the patients who died 
was retrieved from the database of the Kujawsko-Po-
morski and Malopolski regional office of the National 
Health System of Poland. We have analyzed long-
term outcomes after radiotherapy regarding overall 
survival (OS).
ELISA
The blood was collected to a serum collection tube 
both directly prior to radiotherapy and on the fourth 
day following the last radiation dosage. A clot was 
allowed to form at room temperature for 30–60 min-
utes. The tube was placed on ice for 30 minutes in 
order to contract a clot. The serum samples were 
then centrifuged at 3000xg for 10 minutes at room 
temperature. The supernatants 1.0–2.0 ml were col-
lected and stored at -80°C. The analysis of sHLA-G 
concentration in the serum samples was performed 
in the Department of Analytical Biochemistry, Facul-
ty of Biochemistry, Biophysics, and Biotechnology, 
Jagiellonian University. The soluble human leukocyte 
antigen-G (sHLA-G) was detected using the sHLA-G 
sandwich ELISA kit (BioVendor-Exibo, Czech Re-
public). Briefly stated, the blood plasma samples 
were diluted twice and incubated for 1 hour in the 
96-well microplate precoated with the monoclonal 
anti-sHLA-G antibodies. Following incubation, the 
wells were washed and then filled with the monoclonal 
anti-human beta-2-microglobulin antibodies labeled 
with horseradish peroxidase. After an additional 1 hour 
of incubation, the wells were again washed, and the 
colour reaction was developed using tetramethyl ben-
zidine (TMB) substrate. The absorbance values were 
measured at 450 nm on a microplate reader followed 
by the calculation of the sHLA-G concentrations. The 
assay was calibrated using a set of sHLA-G standards 
provided by the producer of the kit.
Statistical analysis
The distribution of variables in the study groups of 
women checked with the use of the Shapiro-Wilk test 
showed that each of the women was different from 
normal. Pre- and postoperative sHLA-G concentra-
tions levels were analyzed using the Wilcoxon test. 
The statistical significance in the levels of sHLA-G, 
both pre- and post treatment, between cervical cancer 
and endometrial cancer patients groups was deter-
mined by the Mann-Whitney Test. The Mann-Whitney 
test was also used for the calculation of differences 
related to FIGO stage and cancer grade. For sur-
vival evaluation, Kaplan-Meier curves analysis was 
performed. 
Results
The statistically significant differences in sHLA-G 
blood serum concentration level were identified be-
fore radiotherapy and on the fourth day following the 
collection of the last dosage of radiotherapy (Me-
dian 5.63 U/ml; range 0.00 – 344.55; vs 5.57 U/ml; 
0.00–94.02; p = 0.04, respectively). The results are 
summarized in Table 2. 
No statistically significant differences were identified 
in the sHLA-G blood serum concentration levels with 
respect to the clinicopathological parameters, such as 
FIGO stage and tumour grade. Similarly, there were no 
differences in pre- and post-treatment sHLA-G levels 
between cervical and endometrial cancer patients. Pre-
treatment sHLA-G levels in the sera of patients with 
I and II stage disease was not significantly different 
from patients with stage III and IV disease (5.63 U/ml, 
range 0–71.82, vs. 5.45 U/ml, range 0–344.55 U/ml, 
P = 0.735). Similarly, the difference in post-treat-
ment levels of sHLA-G was not statistically significant 
(5.75 U/ml, 0–41.28 vs 5.09 U/ml, 0–94.02, P = 0.474). 
The difference in sHLA median levels between well and 
moderately differentiated tumors was not different from 
poorly differentiated tumors, both in pre- and post-treat-
ment evaluation (5.63 U/ml, 0–71.82 vs. 5.45 U/ml, 
0–344.55; P = 0.71 and 5.75 U/ml, 0–41.28 vs. 5.09 U/ml, 
0–94.02 U/ml, P = 0.622). 
We have found significant, negative correlation 
between patients’ age both pre- and postreatment 
and sHLA-G levels (R Spearman = -0.45, P = 0.041; R 
Spearman = -0.46. P = 0.038 respectively).
No statistically significant differences were identified 
in the sHLA-G blood serum concentration levels before 
and after radiotherapy with respect to a long-term out-
come. When patients were divided into two groups: pa-
tients with decreased or stable post-treatment sHLA-G 
levels (Group 1, n = 31) and patients with increased 
post-treatment sHLA-G levels (Group 2, n = 12), there 
were no statistical significant difference in patients’ 
survival (1592 vs. 657 days, P = 0.60; Figure 1). 
Discussion
We have found statistically significant differences 
between the levels of the blood serum concentrations 
of sHLA-G as measured before and after radiother-
apy in patients treated for cervical and endometrial 
carcinomas. Radiotherapy induces single- and dou-
ble-stranded DNA breaks leading to apoptosis [20], but 
it has been shown that RT affects the immune system 
activity, including the induction of a systemic antitumor 
response, with a pro-inflammatory activity and an ab-
scopal effect [21, 22]. RT has also been demonstrated 
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Table 1. Clinicopathological characteristics and treatment modalities of the patients
In this study, we 
analyzed the blood 
serum samples 
obtained from 43 
patients, including
No
Age Cancer FIGO Histopathology Grade Surgery Chemo- 
therapy
1 50 Cervical cancer IB1 squamous cell carcinoma 3 Yes No
2 46 Cervical cancer IB1 squamous cell carcinoma 3 Yes Yes
3 35 Cervical cancer IB2 squamous cell carcinoma 2 No No
4 50 Cervical cancer IIA squamous cell carcinoma 2 No Yes
5 51 Cervical cancer IIA squamous cell carcinoma 3 No Yes
6 48 Cervical cancer IIB squamous cell carcinoma 2 No No
7 65 Cervical cancer IIB adenocarcinoma 2 No Yes
8 65 Cervical cancer IIB squamous cell carcinoma 2 No Yes
9 52 Cervical cancer IIB squamous cell carcinoma 2 No Yes
10 52 Cervical cancer IIB adenocarcinoma 1 No Yes
11 62 Cervical cancer IIB squamous cell carcinoma 3 No Yes
12 42 Cervical cancer IIB squamous cell carcinoma 3 No Yes
13 48 Cervical cancer IIIB squamous cell carcinoma 2 No No
14 63 Cervical cancer IIIB squamous cell carcinoma 1 No No
15 58 Cervical cancer IIIB squamous cell carcinoma 3 No Yes
16 72 Cervical cancer IIIB squamous cell carcinoma 3 No Yes
17 48 Cervical cancer IIIB squamous cell carcinoma 2 No No
18 52 Cervical cancer IIIB squamous cell carcinoma 2 No Yes
19 49 Cervical cancer IIIB adenocarcinoma 2 No Yes
20 47 Cervical cancer IVB squamous cell carcinoma 2 No Yes
21 58 Cervical cancer IIIB squamous cell carcinoma 3 No Yes
22 43 Cervical cancer IIIB squamous cell carcinoma 2 No Yes
23 52 Cervical cancer IIB squamous cell carcinoma 2 No Yes
24 68 Cervical cancer IIA squamous cell carcinoma 2 No Yes
25 62 Cervical cancer IIB squamous cell carcinoma 3 No Yes
26 46 Cervical cancer IB1 squamous cell carcinoma 3 Yes Yes
27 68 Cervical cancer IIA squamous cell carcinoma 2 No Yes
28 48 Cervical cancer IIIB squamous cell carcinoma 2 No No
29 66 Endometrial cancer IB endometrioid 
adenocarcinoma
3 Yes Yes
30 79 Endometrial cancer IB endometrioid 
adenocarcinoma
2 Yes No
31 74 Endometrial cancer IB endometrioid 
adenocarcinoma
3 Yes Yes
32 52 Endometrial cancer IB endometrioid 
adenocarcinoma
2 Yes No
33 61 Endometrial cancer IIIA endometrioid 
adenocarcinoma
2 Yes Yes
34 66 Endometrial cancer IIIB endometrioid 
adenocarcinoma
1 Yes No
Æ
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Table 1 cd. Clinicopathological characteristics and treatment modalities of the patients
In this study, we 
analyzed the blood 
serum samples 
obtained from 43 
patients, including
No
Age Cancer FIGO Histopathology Grade Surgery Chemo- 
therapy
35 74 Endometrial cancer IIIC1 endometrioid 
adenocarcinoma
3 Yes Yes
36 61 Endometrial cancer IIIB endometrioid 
adenocarcinoma
2 Yes No
37 52 Endometrial cancer II endometrioid 
adenocarcinoma
1 Yes No
38 46 Endometrial cancer IIIA serous adenocarcinoma 3 Yes Yes
39 78 Endometrial cancer IIIA serous adenocarcinoma 3 Yes Yes
40 84 Endometrial cancer II undifferentiated carcinoma 3 Yes No
41 70 Endometrial cancer II endometrioid 
adenocarcinoma
1 Yes No
42 74 Endometrial cancer IIIC1 endometrioid 
adenocarcinoma
3 Yes Yes
43 70 Endometrial cancer II endometrioid 
adenocarcinoma
1 Yes No
to exert an immunosuppressive effect, increased levels 
of functionally active Treg lymphocytes were detected 
following radiotherapy [23]. Ionizing radiation has also 
been demonstrated to modulate the HLA-G expres-
sion. Michelin et al. have demonstrated that irradiation 
downregulated cell surface and total HLA-G levels and 
increased sHLA-G1 in the medium of the melanoma 
cell line. Authors concluded that radiotherapy might 
induce a proteolytic cleavage of this molecule [24]. Most 
probably decreasing serum level of sHLA-G observed 
after radiotherapy is linked with reduction of the tumour 
mass that the patients underwent during surgery before 
adjuvant radiotherapy.
The suppression of the immune system constitutes 
a crucial event in the development of malignancy, par-
ticularly in cases of cancer relapse. Surgery, chemo- 
and radiotherapy all have different effects on tumour 
and immune cell interaction [25, 26]. Since, on the 
one hand, the immune system can demonstrate an-
ti-tumour activity, but, on the other hand, can promote 
tumour growth, the degree of the suppressive influence 
of cancer cells on the immune system may be able to 
determine the success of the treatment for a cancer 
relapse [2]. Nevertheless, it is not common practice to 
evaluate the suppressive influence of cancer cells on 
the immune system. This detection could be helpful in 
monitoring treatment processes and might reflect the 
influence of this treatment on the restoration of proper 
immune system activity. sHLA-G, however, has been 
observed in blood sera of patients with gynaecological 
malignancies [15]. Furthermore, sHLA-G has not yet 
been studied in relation to the applied surgery in cases 
of gynaecological malignancies. 
HLA-G expression has been observed in endome-
trial cancer and can be compared with the expression 
reported in various other malignances. In immunohis-
tochemical staining, HLA-G expression varied between 
40% and 55% according to different studies [15, 27]. 
This discrepancy could be the result of the different 
characteristics of the patients included in the study, 
such as being in an advanced stage of the disease or 
having a tumor with non-endometrioid histology. Barrier 
et al. found a correlation between HLA-G expression and 
increasing FIGO stage which could serve as a pre-op-
erative indicator of dissemination [15]. Contrary to our 
study we did not observe a correlation between the 
FIGO stage and the blood serum concentration levels 
of sHLA-G. Most likely this has to do with the character-
Table 2. The difference in pre- and post-treatment serum sHLA-G levels 
Median Range P-value
Pretreatment 5.63 U/ml 0.00–344.55 P = 0.04
Post-treatment 5.57 U/ml 0.00–94.02
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istics of the patients included in the study, where most 
patients have advanced diseases [11]. 
HLA-G expression was associated with disease 
progression in patients with cervical cancer. In the study 
of Li et al., the expression of HLA-G molecule gradually 
increased from preinvasive stages to advanced cancers, 
indicating the role of HLA-G in tumour progression [28]. 
Additionally, Dong et al., indicates, that the HLA-G expres-
sion is related to HPV16/18 infection [29]. However, tissue 
expression of HLA-G may not directly reflect serum levels 
of soluble HLA-G. Similarly to our study, in the paper by 
Samulels et al., patients survival was not influenced by 
serum sHLA-G levels. Additionally, the authors also did 
not find any association between sHLA-G levels and 
clinicopathological characteristic of cervical cancer [30]. 
This serial method of measurement may help to 
reveal the relationship between the applied therapy 
and the size and degree of the suppression of the 
tumour environment. Furthermore, such results could 
indicate that a change in therapy is needed; it could 
also provide a strong, clinical indication and foundation 
for the earlier application of molecular therapies, such 
as immunotherapy. 
Conclusions
The detected sHLA-G blood serum concentrations 
may supply clinically applicable information regarding 
the status of the tumour microenvironment — that is, 
the size and the degree of suppression of the tumour 
environment — where the tumour-immune cell interac-
tion is realized. Finally, this information may also prove 
helpful in the treatment of cancer.
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